Last reviewed · How we verify
Treatment of adult patients with severe hemophilia A with inhibitors — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Gbt021601 | gbt021601 | Pfizer | unknown | unknown |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of adult patients with severe hemophilia A with inhibitors
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of adult patients with severe hemophilia A with inhibitors:
- Treatment of adult patients with severe hemophilia A with inhibitors treatment updates — RSS
- Treatment of adult patients with severe hemophilia A with inhibitors treatment updates — Atom
- Treatment of adult patients with severe hemophilia A with inhibitors treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of adult patients with severe hemophilia A with inhibitors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-adult-patients-with-severe-hemophilia-a-with-inhibitors. Accessed 2026-06-10.
Related
- Treatment of adult patients with severe hemophilia A with inhibitors full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing